Signed and dated written informed consent obtained from the subject

Males and females of age 18 years and older at the time of screening

Established diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology classification criteria

Documented renal biopsy evidence of proliferative glomerulonephritis prior to screening

Urine protein-to-creatinine ratio \> 0.5 (mg/mg)

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis